Compare Cigna Corp (CI) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Rocket Lab USA Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Rocket Lab USA Inc trades at $80.57 (market cap $50.01B). The key difference: Cigna Corp is the larger of the two by market cap, and Cigna Corp pays a 2.24% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| CI | RKLB | |
|---|---|---|
Market Cap | $73.56B | $50.01B |
Sector | Health | Technology |
52-Week High | $311.00 | $150.23 |
52-Week Low | $244.41 | $39.48 |
Enterprise Value | $98.27B | $47.84B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
Rocket Lab (RKLB) trades at $82.83, up 9.46% today, reflecting strong momentum despite recent volatility. The stock shows a bullish technical setup with key resistance at $85 and support at $79, while fundamentals reveal rapid revenue growth—Q2 2026 revenue surged 62% to $234.1 million—but persistent losses, with a net income margin of -26.87%. Analyst sentiment is overwhelmingly positive, with 76% buy ratings and a $115.11 consensus target, though cash burn and Neutron rocket costs pose execution risks.
The outlook hinges on scaling launch services and space systems to achieve profitability, backed by a record $2.36 billion backlog. Near-term catalysts include Q3 earnings and European expansion, but investors face risks from high valuations (P/S of 60.8) and competitive pressure from SpaceX. Upside potential exists if margin improvements materialize, but the stock remains speculative given its loss-making profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
